Cite
Moyle GJ, Bouza E, Antunes F, et al. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee. Antivir Ther. 1997;2(4):229-36
Moyle, G. J., Bouza, E., Antunes, F., Smith, D., Harris, R., Warburg, M., & Walker, M. (1997). Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee. Antiviral therapy, 2(4), 229-36.
Moyle, G J, et al. "Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee." Antiviral therapy vol. 2,4 (1997): 229-36.
Moyle GJ, Bouza E, Antunes F, Smith D, Harris R, Warburg M, Walker M. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee. Antivir Ther. 1997 Dec;2(4):229-36. PMID: 11327442.
Copy
Download .nbib